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Selective Intra-Arterial Calcium Stimulation
with Hepatic Venous Sampling for
Preoperative Localization of Insulinomas
Objective: To determine the value of selective intra-arterial calcium stimulation
with hepatic venous sampling using serum insulin and C-peptide gradients for the
preoperative localization of insulinomas.
Materials and Methods: Seven consecutive patients [three men and four
women aged 15 77 (mean, 42.7) years] with hypoglycemia underwent selective
intra-arterial calcium stimulation in conjunction with hepatic venous sampling.
Insulin gradients were calculated by an individual blinded to all other preoperative
imaging studies and operative findings. In all patients except one, C-peptide gra-
dients were also analyzed. The results were compared with the preoperative find-
ings of ultrasonography, computed tomography, arteriography and endoscopic
ultrasonography, as well as with the intraoperative findings of ultrasonography
and palpation at surgery. 
Results: Eight insulinomas (mean diameter, 12.5 mm) were diagnosed after
surgery. In six patients, the calcium stimulation test with insulin gradients allowed
accurate localization of the pathologic source of insulin secretion. Both C-peptide
and insulin gradients substantially increased diagnostic accuracy. In one patient,
C-peptide gradients were more helpful than insulin gradients for tumor localiza-
tion.
Conclusion: Selective intra-arterial calcium stimulation with hepatic venous
sampling is a highly accurate and safe method for the preoperative localization of
insulinomas. Additional C-peptide gradients seem to be helpful in assessing
tumor location, but further study is needed.
ancreatic insulinoma is a relatively rare endocrine tumor with an estimat-
ed occurrence rate of 4 cases per million person-years (1). Thus, few clini-
cians or even referral centers have extensive experience of the condition.
Most insulinomas are small, and 90% are smaller than 2 cm (2). Although 90% of
these tumors are benign, they are still potentially fatal due to the risk of lethal hypo-
glycemia (3). If patients successfully undergo curative surgical resection (4, 5), they
have a normal life expectancy (1). 
Insulinoma can be confirmed by demonstrating that during hypoglycemia the plasma
insulin level is inappropriately high, and modern suppression tests based upon this fact
allow verification with a high degree of confidence (6). Preoperative localization of an
insulinoma is a crucially important step after diagnosis, and leads to significant reduc-
tions in operative time (2). 
In 1991, Doppman et al. (7) reported four cases in which insulinomas were success-
fully localized using 0.01 0.025 mEq/kg calcium gluconate as the secretagogue. In
1993, authors from the same institution reported the successful localization of six addi-
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Ptional tumors (8). Other recent studies have shown that se-
lective intra-arterial stimulation with hepatic venous sam-
pling using intra-arterial calcium as the insulin secreta-
gogue is a powerful technique for the localization of occult
insulinomas (4, 7 12). Doppman et al. (8) found, however,
that elevated hepatic venous insulin levels did not always
equate with correct localization: unequivocal localization
was reported in only five of nine patients (56%) but a gra-
dient was demonstrated in all nine. Thus, we supposed that
additional analysis of C-peptide gradients would be helpful
in assessing the location of a tumor when insulin gradients
are equivocal. 
The purpose of our study was to demonstrate the value
of selective intra-arterial calcium stimulation with hepatic
venous sampling (ASVS), using serum C-peptide and in-
sulin gradients for the localization of insulinomas. The re-
sults of ASVS were compared with the preoperative find-
ings of US, CT, angiography, and endoscopic US (EUS), as
well as with the findings of intraoperative US (IOUS) and
palpation at surgery. 
MATERIALS AND METHODS
Patients
Seven consecutive patients [three men and four women
aged 15 77 (mean, 42.7) years] admitted to our hospital
with hypoglycemia between April 1, 2001 and September
31, 2002 were retrospectively studied. The time from the
onset of neuroglycopenic symptoms to diagnosis ranged
from 4 to 42 months. The age, sex, and history of the pa-
tients are summarized in Table 1. The inclusion criteria
were coexisting hypoglycemic symptoms with low fasting
serum glucose levels (<50 mg/dL) and biochemical evi-
dence of organic hyperinsulinemia, confirmed by a fasting
test (serum insulin:glucose ratio (0.3, with high C-peptide
levels). Symptomatic hypoglycemia was observed and doc-
umented [plasma glucose range: 27 46 (mean, 35) mg/dl]
after 24 72 hours of fasting. Concomitant insulin [range:
10.9 33.6 (mean, 18.4)  IU/ml] and C-peptide levels
[range: 1.95 5.67 (mean, 3.95) ng/ml] were not suppressed.
All these patients had pathologic glucose-insulin ratios
(range, 0.40 0.73; mean, 0.51). Thus, hyperinsulinemic hy-
poglycemia due to insulin-secreting tumors was proven in
all cases. Fasting test results are summarized in Table 1.
Imaging studies
Radiological imaging modalities employed for the local-
ization of these pancreatic adenomas are summarized in
Table 2. Ultrasonography (US) was performed in three cas-
es, endoscopic ultrasonography (EUS) in two, computed
tomography (CT) in seven, and intraoperative ultrasonog-
raphy (IOUS) in four. In all cases, pancreatic angiography
formed part of the calcium stimulation test. The detection
rate of each study was evaluated. 
ASVS technique and interpretation
After obtaining informed consent from each patient,
ASVS was performed according to the protocol proposed
by Doppmann et al. (8). Additional C-peptide sampling
had also been consented to. None of our patients was re-
ceiving cardiac glycosides, and none was suffering from
sarcoidosis or renal failure, conditions considered relative
contraindications to intra-arterial calcium injection. All
tests were carried out under local anesthesia and with con-
tinuous electrocardiographic and blood pressure monitor-
ing. To avoid iatrogenic hypoglycemia, blood sugar levels
were checked before the procedure. In patient 2, this was
37 mg/dl, and 25 g of intravenous glucose were adminis-
tered, using a 50% solution. 
Prior to angiography, a 5-French (F) Cobra catheter
(Terumo, Tokyo, Japan) was placed in the right hepatic
vein close to its junction with the inferior vena cava
through a puncture site in the right internal jugular vein
(Fig. 1). The left hepatic vein was not catheterized. The
right femoral artery was then punctured, and a 5-F Yashiro
catheter (Terumo) was advanced to the celiac trunk and
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Table 1. Patient Data and Fasting Test Results
Patient
Age 
Sex
History  Fasting glucose nadir Insulin 
Insulin/glucose ratio
b C-peptide
(years) (months) (mg/dl) ( IU/ml)
a (ng/ml)
c
1 41 M 24 30 15.6 0.52 2.80
2 59 F 20 37 15.1 0.41 4.48
3 15 M 36 46 33.6 0.73 4.40
4 19 M 18 27 10.9 0.40 5.67
54 4 F 04 39 20.3 0.52 4.40
6 44 F 42 30 14.6 0.49 1.95
77 7 F 04 40 17.8 0.45 2.55
Note.─
a Normal range of insulin : 2 25  IU/ml, 
b Insulin ( IU/ml):glucose (mg/dl) ratio  0.3 = pathologic, 
c Normal range of C-peptide : 0.33 3.81 ng/mlthe superior mesenteric artery (SMA). Occasionally, a 3-F
Progreat microcatheter (Terumo) was used for coaxial su-
perselective catheterization of the gastroduodenal (GDA)
and splenic artery (SpA). Selective presampling angiogra-
phy was performed after selectively injecting nonionic con-
trast agent (Iomeron 300; Ilsung, Korea) into the GDA,
SpA, and SMA. For angiographic studies, digital subtrac-
tion angiography (DSA) was used (Fig. 1).
Immediately after each such study, a 5-ml bolus of calci-
um gluconate (0.025 mEq Ca
2+/kg) diluted in saline was
rapidly injected through the proximally positioned catheter
in each selectively catheterized artery. The period between
each injection was at least 5 minutes. Before and 30, 60,
and 120 seconds after calcium injection, 5 ml of hepatic ve-
nous blood was obtained. Each sample was labeled accord-
ing to the time interval and artery of origin, and cen-
trifuged, and the resulting serum was assayed for insulin
concentration in all patients and C-peptide concentration
in six.
The accuracy of ASVS in localizing pancreatic insulino-
mas was retrospectively determined. All ASVS results
were analyzed by an individual blinded to all other preop-
erative imaging studies and operative findings. According
to the findings of Doppman et al., a positive finding is indi-
cated by a twofold elevation of insulin levels in the 30- or
60-second samples (or both) obtained from the hepatic
vein (1). A twofold rise in insulin levels following calcium
gluconate injection of the GDA or SMA indicates that the
tumor is located in the pancreatic head or uncinate process;
a twofold rise after injection into the SpA suggests a corpo-
real or caudal location. For diagnostic accuracy, C-peptide
gradients in all patients except patient 1 were also ana-
lyzed. The diagnostic criteria for C-peptide have not been
reported, but we supposed that such analysis would be use-
ful if insulin gradients were equivocal. The additional utili-
ty of C-peptide gradients will be discussed later. 
The results of ASVS in which insulin gradients only were
determined, and in which additional C-peptide gradients
were established, were compared. Comparisons were also
made between the sensitivity of these modalities and that
of other localizing modalities in terms of the operative
findings and outcome of surgery. 
Confirmative diagnosis and follow-up
All patients later underwent surgery, preferably enucle-
ation of the adenoma. Routine bimanual palpation was ap-
plied in all cases, and IOUS in four. The ASVS results were
compared with the operative findings and the outcome of
surgery.
The median follow-up time was 4 (range, 1 10) months.
At these intervals, patient histories were obtained and plas-
ma glucose levels were determined after 24 72 hours of
fasting.
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Fig. 1. A 5-French Cobra catheter (arrow) was placed in the right
hepatic vein close to its junction with the inferior vena cava
through a puncture of the right internal jugular vein. Selective
splenic arteriogram shows no abnormal staining.
Table 2. Results of Preoperative Imaging Studies, ASVS Technique, and Surgery
a
Patient US EUS CT IOUS Arteriography ASVS Surgery Tumor size (mm)
1+ N D ND H or U Head 15
2 + ND + ND + H or U Head 10
3 ND + ND + B or T Tail 25
4N D + + + B or T Tail 2 5, 10
5N D N D + H or U Uncinate process 7
6N D + + + H or U Uncinate process 20
7N D N D + H or U Head 8
Note.─
aUS=ultrasonography, EUS=endoscopic ultrasonography, IOUS=intraoperative ultrasonography, ASVS=selective intra-arterial calcium stimulation
with hepatic venous sampling, ND=not done, +=tumor localized,  =no tumor localized, H or U=head or uncinate process, B or T=body or tailRESULTS
The results of all localization studies and surgery are pre-
sented in Table 2. 
In no case did ASVS lead to complications, and proce-
dural-related symptomatic hypoglycemia and hypercal-
cemia were not encountered. Insulin or C-peptide gradi-
ents were calculated as the ratios of hepatic venous insulin
or C-peptide concentrations, respectively, at 30, 60, and
120 seconds after ASVS to baseline.
In patients 1, 2, 5 and 7, significant insulin gradients
were observed after calcium injection into the GDA and in
patient 6 after stimulation of the GDA and SMA, indicat-
ing the presence of insulinomas in the pancreatic head or
uncinate process (Fig. 2A). In patients 2, 5, 6 and 7, C-pep-
tide gradients were also significant (Fig. 2B), and in patient
3, both insulin and C-peptide gradients increased signifi-
cantly after stimulation of the SpA, suggesting that the
pathological source of insulin might be the pancreatic body
or tail (Fig. 3). 
A diagnostic problem occurred only in patient number
4. Peak insulin gradients in the GDA 30 seconds after
stimulation and in the SpA at 60 seconds were not signifi-
cantly different (Fig. 4A). Moreover, after 30 seconds, in-
sulin gradients decreased gradually in the GDA, but in the
SpA showed a gradual increase. The analyst, blinded to all
other preoperative imaging studies and operative findings,
thus could not confidently determine the location of the
insulinoma. In this case, additional C-peptide gradients
were, however, helpful (Fig. 4B). The C-peptide gradient
peaked 60 seconds after stimulation of the SpA, and in the
GDA was not more than 1.0. The analyst finally deter-
mined that the tumor location was the pancreatic body or
tail. 
Eight insulinomas, 5 25 (mean, 12.5) mm in size, were
found and confirmed histopathologically after enucleation
(Table 2). All tumors except in patient 3 were less than 2
cm in size. Three were in the head, two in the uncinate
process and three in the tail. In patient 4, two small adeno-
mas were detected in the pancreatic tail.
The tumors were correctly localized by US in two of
three patients (sensitivity, 67%), by EUS in one of two
(sensitivity, 50%), by CT in four of seven (sensitivity,
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Fig. 2. A 59-year-old woman with an insulinoma of the pancreatic
head (patient 2).
A. Selective intra-arterial calcium injection demonstrates a 21-fold
insulin gradient in the gastroduodenal artery at 30 secs. 
B. In the same artery, a six-fold C-peptide gradient was also noted
at 30 secs.
C. Gastroduodenal arteriogram demonstrates tumor blush (arrow)
within the pancreatic head. 
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Splenic57%), by angiography in three of seven (sensitivity, 43%),
and by IOUS in four of four (sensitivity, 100%).
For insulin gradients only, the sensitivity of ASVS was
86% (6 of 7 patients), but with additional C-peptide gradi-
ents, sensitivity was 100% (6 of 6 patients).
All patients were cured by enucleation of the insulinoma
and remained free of hypoglycemia during the follow-up
period. 
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Fig. 3. A 15-year-old youth (patient 3) with an insulinoma of the pan-
creatic tail.
A. In the splenic artery, the insulin gradient peaked at 30 secs. 
B. In the same artery, the C-peptide gradient also peaked at 30 secs. 
C. Splenic arteriogram shows tumor staining (arrow) within the pan-
creatic tail.
AB
C
Fig. 4. A 19-year-old male (patient 4) with two insulinomas of the pancreatic tail.
A. Insulin gradients show no significant difference between the GDA 30 secs after calcium stimulation and the SpA at 60 secs. Moreover,
after 30 secs, insulin in the gastroduodenal artery decreased gradually, but in the splenic artery a gradual increase was observed. The
analyst could not determine the location of the insulinomas. 
B. In the splenic artery, the C-peptide gradient peaked 60 secs after stimulation but in the gastroduodenal artery, the gradient was not
more than 1.0. The analyst localized the tumor to the pancreatic body or tail. 
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The availability of methods to accurately determine cir-
culating levels of insulin, C-peptide, and proinsulin has led
to dramatic improvements in the preoperative diagnosis of
insulinomas, and to exclusion of the surreptitious adminis-
tration of insulin as the cause of hypoglycemia (3). Preop-
erative localization of a tumor has, for this reason, moved
to center stage as the main focus of interest.
Since Daggett et al. (6) published their findings in 1981,
the question of whether imaging is necessary prior to initial
insulinoma-related surgery has been a matter of debate
(13-15). Many surgical teams, meanwhile, do not rely ex-
clusively on bimanual palpation of the pancreas combined
with IOUS, but insist on meticulous preoperative localiza-
tion, and it is to this that they attribute their high operative
success rates (16 18). An average of 10% of insulinomas
defy surgical exploration (4, 16) and correct preoperative
localization minimizes the extent to which this is neces-
sary, thus reducing morbidity (13). Recent developments in
the laparoscopic resection of pancreatic insulinomas, a pro-
cedure increasingly described for tumors located in the
body or tail of the pancreas, emphasize, furthermore, the
need for an accurate preoperative localization procedure
(19, 20). Hence, even though they are controversial in
terms of cost-effectiveness (3, 22), preoperative localiza-
tion studies are recommended (13, 15 17, 21). If such stud-
ies do not facilitate rational and safe surgical enucleation or
resection, they are not, however, time- and cost-effective
(23). 
The mean diameter of insulinomas is generally not more
than 15 mm (2, 11, 15, 24), and non-invasive imaging
modalities thus often fail to localize them. Non-invasive
modalities such as US, CT, and MRI have shown low sensi-
tivities (8, 9, 13, 14, 16, 21, 25), while CT and US will de-
tect up to 60% of biochemically proven insulinomas.
Relatively little has so far been reported about MRI in the
diagnosis of islet cell tumors, and its exact role is uncertain
(4). In our series the mean size of insulinomas was 12.5
mm, a fact which could explain the low detection rate of
adenomas at US and CT. However, recent reports describ-
ing the findings of dynamic CT and MRI have been promis-
ing (26 28).
The sensitivities of other, invasive, localization tech-
niques for detecting insulinomas were higher: 57-82% with
EUS (11, 12, 18, 29, 30), 35% to 65% with angiography
(9, 10, 31, 32), and 77-100% with transhepatic portal ve-
nous sampling (TPVS) (7 10, 13, 14, 17, 21, 31, 32).
However, these techniques have certain disadvantages, in-
cluding low sensitivity in the case of angiography and EUS
(the sensitivity of EUS depends on the location of the tu-
mor) and higher morbidity for TPVS (4, 8, 9, 33).
The sensitivity of IOUS combined with palpation was
more than 80% in most reported series (2 4, 14, 16, 31,
34). However, insulinomas located in the pancreatic head
or uncinate process, and thus deep within the parenchyma,
were difficult or impossible to palpate, even where an ex-
perienced surgeon was involved (5), and to detect at
surgery, using IOUS, particularly at hospitals with limited
experience of this modality (9, 11, 31). 
With ASVS, as introduced by Doppman et al. in 1991 (3,
7), the detection of insulinomas is based on their hormone
production, not their appearance. The sensitivity of the
technique is independent of lesion size. At the same time,
however, since the lesion is identified by its hormone out-
put, it is not visulalized directly and cannot be located pre-
cisely. Its position can be confirmed only in terms of a re-
gion of the pancreas (head/uncinate process versus
body/tail). Decisions as to the method of treatment are not,
however, problematic. Adenomas to the left of the SMA
can be treated by enucleation and distal pancreatectomy,
whereas those to the right require enucleation. In our se-
ries, enucleation was preferred. Moreover, ASVS is far less
invasive and complicated than TPVS and can be safely car-
ried out in combination with a normal DSA procedure (5,
8, 9).
Complications of ASVS are rare (33), and major compli-
cations did not occur in our patients. Although hypo-
glycemia is a severe, even life-threatening potential com-
plication of ASVS, it has not previously been reported (4).
Insulin levels in the hepatic vein usually peaked in samples
obtained 30 or 60 seconds after calcium stimulation, and
were often returning toward baseline within 120 seconds
of stimulation, suggesting that insulin release is confined to
the short interval during which beta cells are exposed to
high serum calcium levels (9). Calcium should be adminis-
tered cautiously to patients with sarcoidosis, or renal or
cardiac disease, particularly to those receiving cardiac gly-
cosides (7). The inotropic effects of cardiac glycosides and
calcium are synergistic; if both are administered simultane-
ously, dysrhythmia may thus occur (33). The injection of
calcium can also lead to pancreatitis (8, 33). 
A diagnostic problem occurred only in patient 4. Insulin
gradients in the GDA 30 seconds after stimulation and in
the SpA at 60 seconds were not significantly different, and
while this gradient peaked 30 seconds after the start of cal-
cium gluconate infusion into the GDA, in the SpA it in-
creased gradually. Additional analysis of the C-peptide
gradient showed that in the SpA it peaked 60 seconds after
stimulation, and in the GDA it was not more than 1.0. The
analyst localized the tumor to the pancreatic body or tail,
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of the SMA.
Elevated insulin levels in the hepatic veins after ASVS
did not always equate with correct localization (8). We as-
sumed that additional analysis of C-peptide gradients
would help assess the location of a tumor when insulin gra-
dients are equivocal, basing our assumption on two factors:
first, calcium gluconate administration led not only to hy-
perinsulinemia, but also to increased serum proinsulin and
C-peptide levels (35). Second, although the secretory ratio
of C-peptide to insulin is 1:1, the ratio in serum is about
5:1 to 15:1 (36). The molar concentration of C-peptide in
blood is higher than that of insulin because of the hepatic
clearance of the latter (36). Approximately 50% of insulin
is rapidly removed by its initial passage through the liver,
but hepatic extraction of C-peptide is negligible (36). A rel-
atively high concentration of C-peptide may thus reflect a
subtle increase in its level, compared to that of insulin, af-
ter stimulation with calcium gluconate.
In six of our patients, the sensitivity of C-peptide gradi-
ents for localizing insulinoma was 100%. To our knowl-
edge, this is the first report to describe the use of these gra-
dients in ASVS for the localization of insulinomas.
However, to confirm the efficacy of C-peptide gradients, in
spite of the significant additional cost of multiple C-peptide
assays, further investigation is needed.
A further point is that because catheterization of the left
hepatic vein was technically more difficult, and also unnec-
essary, the right hepatic vein only was chosen (4, 8, 9, 19,
24). Thus, the amount of sampling required was also re-
duced. Selective distribution of splenic and mesenteric ve-
nous blood to the left and right portal vein, respectively,
may mask an adenoma in the body-tail region, but such
portal flow dynamics have never been proven (24).
Moreover, Lo et al. (19) reported that where ASVS was
used, there was no difference in the degree of step-up be-
tween right and left hepatic vein sampling. Doppman et al.,
furthermore, observed that in patients with tumors in the
body and tail of the pancreas, insulin levels in samples ob-
tained from the right hepatic vein were always elevated
(9).
In conclusion, ASVS is a highly accurate and safe method
for the preoperative localization of insulinomas. Additional
C-peptide gradients seem to be helpful in assessing the lo-
cation of a tumor, but additional investigation is needed. 
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